baseline characteristics: hps
DESCRIPTION
Baseline Characteristics: HPS. Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. HPS: Mean SE Differences in Lipids (Simvastatin – Placebo). Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016. Risk ratio and 95% CI. 0.4. 0.6. 0.8. 1.0. 1.2. - PowerPoint PPT PresentationTRANSCRIPT
Slide Source:Lipids Online Slide Librarywww.lipidsonline.org
DiabetesDiabetes(n=5,963)(n=5,963)
No DiabetesNo Diabetes(n=14,573)(n=14,573)
Age, years 62.1 64.7
Men 4,147 (70%) 11,307 (78%)
Current smokers 758 (13%) 2,155 (15%)
Vascular disease
Prior MI 1,125 (19%) 7,385 (51%)
Other CHD 856 (14%) 4,020 (28%)
Other vascular 1,070 (18%) 2,930 (20%)
No vascular 2,912 (49%) 238 (2%)
Baseline Characteristics: HPSBaseline Characteristics: HPS
Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.
Slide Source:Lipids Online Slide Librarywww.lipidsonline.org
Lipids, mg/dlLipids, mg/dlDiabetesDiabetes(n=5,963)(n=5,963)
No Diabetes No Diabetes (n=14,573)(n=14,573)
TC –42.5 1.55 –46.4 0.77
LDL-C –34.8 1.16 –38.7 0.77
HDL-C +0.4 0.39 +1.5 0.39
TG –26.6 5.31 –26.6 2.66
HPS: MeanHPS: MeanSE Differences in LipidsSE Differences in Lipids(Simvastatin – Placebo)(Simvastatin – Placebo)
Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.
Slide Source:Lipids Online Slide Librarywww.lipidsonline.org
Risk ratio and 95% CIRisk ratio and 95% CI
VASCULAR EVENTSVASCULAR EVENTSSIMVASTATINSIMVASTATIN
(10,296)(10,296)PLACEBOPLACEBO(10,267)(10,267)
Major coronary events 898 (8.7%) 1212 (11.8%)
Diabetes 279 (9.4%) 377 (12.6%)
No diabetes 619 (8.5%) 835 (11.5%)
Strokes 444 (4.3%) 585 (5.7%)
Diabetes 149 (5.0%) 193 (6.5%)
No diabetes 295 (4.0%) 392 (5.4%)
Revascularizations 939 (9.1%) 1205 (11.7%)
Diabetes 260 (8.7%) 309 (10.4%)
No diabetes 679 (9.3%) 896 (12.3%)
Major vascular events 2033 (19.8%) 2585 (25.2%)
Diabetes 601 (20.2%) 748 (25.1%)
No diabetes 1432 (19.6%) 1837 (25.2%)
HPS: Major Vascular Events by Prior DiabetesHPS: Major Vascular Events by Prior Diabetes
STATIN Better
PLACEBO Better
Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.Reprinted with permission from Elsevier Science.
0.6 0.8 1.0 1.2 1.40.4
27% reduction 27% reduction (15–38)(15–38)
p<0.0001p<0.0001
24% reduction 24% reduction (6–39)(6–39)p=0.01p=0.01
17% reduction 17% reduction (3–30)(3–30)p=0.02p=0.02
22% reduction 22% reduction (13–30)(13–30)
p<0.0001p<0.0001
Slide Source:Lipids Online Slide Librarywww.lipidsonline.org
HPS: Major Vascular Events by Year in HPS: Major Vascular Events by Year in Patients with DiabetesPatients with Diabetes
0
5
10
15
20
25
30
0 1 2 4 5 63
PlaceboPlacebo
SimvastatinSimvastatin
Pati
ents
wit
h E
vents
(%
)
–1(6) 13(8) 47(10) 51(15) 58(48)34(9)Benefit/1000 (SE)
Logrank Logrank p<0.00001p<0.00001
Years of Follow-up
Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.Reprinted with permission from Elsevier Science.
Slide Source:Lipids Online Slide Librarywww.lipidsonline.org
LDL-CLDL-CSIMVASTATINSIMVASTATIN
(10,296)(10,296)PLACEBOPLACEBO(10,267)(10,267)
<116 mg/dl
Diabetes 191 (15.7%) 252 (20.9%)
No diabetes 407 (18.8%) 504 (22.9%)
116 mg/dl
Diabetes 410 (23.3%) 496 (27.9%)
No diabetes 1025 (20.0%) 1333 (26.2%)
ALL PATIENTS 2033 (19.8%) 2585 (25.2%)
HPS: Major Vascular Events by LDL-C and HPS: Major Vascular Events by LDL-C and Prior DiabetesPrior Diabetes
Risk ratio and 95% CIRisk ratio and 95% CI
STATIN Better
PLACEBO Better
0.6 0.8 1.0 1.2 1.40.4
27% reduction 27% reduction (13–40)(13–40)
p=0.0007p=0.0007
Heart Protection Study Collaborative Group. Lancet 2003;361:2005–2016.Reprinted with permission from Elsevier Science.